Sinha, Arjun D.Agarwal, Rajiv2020-07-312020-07-312019-05-07Sinha, A. D., & Agarwal, R. (2019). Clinical Pharmacology of Antihypertensive Therapy for the Treatment of Hypertension in CKD. Clinical journal of the American Society of Nephrology : CJASN, 14(5), 757–764. https://doi.org/10.2215/CJN.04330418https://hdl.handle.net/1805/23467CKD is common and frequently complicated with hypertension both predialysis and in ESKD. As a major modifiable risk factor for cardiovascular disease in this high-risk population, treatment of hypertension in CKD is important. We review the mechanisms and indications for the major classes of antihypertensive drugs, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, β-adrenergic blocking agents, dihydropyridine calcium channel blockers, thiazide diuretics, loop diuretics, mineralocorticoid receptor blockers, direct vasodilators, and centrally acting α-agonists. Recent evidence suggests that β-adrenergic blocking agents may have a greater role in patients on dialysis and that thiazide diuretics may have a greater role in patients with advanced CKD. We conclude with sharing our general prescribing algorithm for both patients with predialysis CKD and patients with ESKD on dialysis.en-USPublisher PolicyAntihypertensive AgentsSodium Chloride Symporter InhibitorsAngiotensin-Converting Enzyme InhibitorsSodium Potassium Chloride Symporter InhibitorsCalcium Channel BlockersNR3C2 proteinHumanReceptorsMineralocorticoidVasodilator AgentsRisk factorsPharmacologyClinicalRenal dialysisAdrenergic beta-AntagonistsKidney FailureChronicHypertensionAngiotensin Receptor AntagonistsAlgorithmsDihydropyridinesArticle